Cybersecurity Measures and Metrics for Medical Devices

Key Takeaways

• Measures are quantifiable attributes, metrics are calculations from measures.
• FDA requires tracking vulnerability patching percentage and durations.
• Data collection applies to pre-market plans and post-market reports.
• Prioritize vulnerabilities by risk profiles for effective remediation.
• Actionable insights from data drive continuous security improvements.
• Plan for data collection even if data isn't immediately available.

Table of Contents

• Key Takeaways
• Understanding the Distinction Between Measures and Metrics
• What the FDA Expects: Measures and Metrics for Medical Device Cybersecurity
• Addressing the Challenges of Measure and Metric Collection
• Incorporating Risk Profiles and Actionable Insights
• Navigating the Regulatory Landscape: When to Include Measures and Metrics

Why this matters

Effective cybersecurity measures and metrics are foundational for ensuring the safety and efficacy of medical devices. Without transparent, verifiable data, manufacturers cannot accurately assess their security posture or demonstrate compliance with regulatory expectations. The stakes are high: potential patient harm, data breaches, and significant regulatory penalties. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, explicitly mandates that manufacturers establish clear processes for collecting and analyzing cybersecurity data throughout the device lifecycle. This includes providing specific metrics during pre-market submissions and in post-market surveillance. Adherence to standards such as IEC 81001-5-1, ISO 27001, and AAMI TIR57 guides the formulation of these measures and metrics, but the FDA guidance provides the mandatory framework. Manufacturers must move beyond merely having security controls to actively proving their effectiveness through quantifiable data. This data drives not only compliance but also continuous improvement, ultimately safeguarding patients and preserving public trust in medical technology.

Understanding the Distinction Between Measures and Metrics

In the world of medical device cybersecurity, the terms “measures” and “metrics” are often used interchangeably; however, they represent distinct concepts that are crucial to understand, especially when navigating the regulatory landscape established by the U.S. Food and Drug Administration (FDA).

As Christian Espinosa and Trevor Slattery, the hosts of the Med Device Cyber Podcast, explain, a measure is a quantifiable attribute, such as the time it takes to apply a software patch or the number of security incidents that have occurred. On the other hand, a metric is a calculation derived from one or more measures, typically expressed as a percentage or ratio. For example, the percentage of identified vulnerabilities that have been patched is a metric, while the time it takes to patch those vulnerabilities is a measure.

This distinction is crucial because the FDA has very specific expectations regarding the measures and metrics that medical device manufacturers must track and report. Failing to understand the difference can lead to confusion and potentially jeopardize the regulatory approval process.

What the FDA Expects: Measures and Metrics for Medical Device Cybersecurity

According to the guidance provided by the FDA, there are three key measures and metrics that medical device manufacturers must focus on:

• Percentage of identified vulnerabilities that are updated or patched - This metric represents the proportion of known vulnerabilities that have been addressed through software updates or patches.
• Duration from vulnerability identification to patch availability - This measure tracks the time it takes to develop and release a patch or update to address a vulnerability that has been identified.
• Duration from patch availability to patch deployment - This measure focuses on the time it takes to actually roll out the patch or update to all fielded devices.

These measures and metrics are crucial because they provide the FDA with a clear understanding of how medical device manufacturers proactively identify, address, and mitigate cybersecurity vulnerabilities throughout the product’s lifecycle.

It’s essential to note that the FDA’s expectations regarding these measures and metrics extend beyond the initial device submission process. In fact, the agency requires manufacturers to continue collecting and reporting on this data as part of their post-market surveillance efforts, which are typically submitted through annual reports or other regulatory filings.

Addressing the Challenges of Measure and Metric Collection

While the FDA’s requirements may seem straightforward, the reality of collecting and reporting on these measures and metrics can be more complex, especially for medical device manufacturers that may not have robust cybersecurity monitoring and incident response processes in place.

One of the key challenges is the sheer volume of vulnerabilities that can be identified in medical devices, particularly as the complexity of these devices continues to increase. As Espinosa and Slattery point out, it’s not uncommon for a single device to have hundreds or even thousands of identified vulnerabilities. Triaging and prioritizing these vulnerabilities based on their risk profile is crucial, as the FDA is primarily concerned with the remediation of critical and high-risk vulnerabilities.

Another challenge is the lack of real-time monitoring and alerting capabilities on many medical devices. Unlike traditional IT systems that are often integrated with security operations centers (SOCs) and other monitoring tools, many medical devices operate in relative isolation, with limited visibility into security events and incidents. To address this, Espinosa and Slattery recommend that medical device manufacturers design their products with built-in alerting mechanisms that can notify users of anomalies or security events in a clear and actionable way.

Additionally, the FDA’s focus on measures and metrics related to patch management and deployment highlights the importance of having a well-defined and efficient patching process. This can be particularly challenging for medical devices that may be deployed in a variety of environments, from hospitals to private homes, each with its own unique security considerations and constraints.

Incorporating Risk Profiles and Actionable Insights

See also: De Novo Cybersecurity Requirements: What the FDA Expects, FDA Cybersecurity Major vs Minor Deficiency: How Reviewers Grade Findings, and FDA Cybersecurity Deficiencies in PMA Submissions: AI Requests, Major Deficiencies, and Complete Response Letters.

While the FDA’s requirements for measures and metrics provide a solid foundation for medical device cybersecurity, Espinosa and Slattery emphasize that these data points should not be viewed as the end goal, but rather as a starting point for more comprehensive security efforts.

One key aspect that the hosts highlight is the importance of incorporating risk profiles into the collection and analysis of cybersecurity measures and metrics. The level of risk associated with a particular vulnerability or security event can vary significantly depending on the device’s intended use, the environment in which it is deployed, and the potential impact on patient safety and care.

For example, a medical device used in a hospital setting may face a higher risk profile than one used in a home environment, due to factors such as the increased likelihood of network-based attacks and the potential for more sophisticated threat actors. By understanding these nuanced risk profiles, medical device manufacturers can prioritize their remediation efforts and ensure that the most critical vulnerabilities are addressed in a timely manner.

Additionally, Espinosa and Slattery stress the importance of making the collected measures and metrics actionable, rather than simply focusing on compliance. This means using the data to drive meaningful improvements in the device’s security posture, such as optimizing patch management processes, enhancing incident response capabilities, and implementing more robust security controls.

Navigating the Regulatory Landscape: When to Include Measures and Metrics

One common misconception that Espinosa and Slattery address is the timing of when medical device manufacturers need to include measures and metrics in their regulatory submissions. The hosts explain that the requirement to provide this data is not always applicable, especially for new devices or those without a predicate device to reference.

For devices that are being submitted for the first time, the FDA does not necessarily expect the manufacturer to have a complete set of measures and metrics ready for the initial submission. Instead, the agency requires that the manufacturer provide a plan for how they intend to collect and report on these data points in the post-market phase.

However, for devices that have a predicate or previously approved version, the FDA may expect the manufacturer to have a more robust set of measures and metrics available, as they should have been collecting this data for the existing product. In these cases, the manufacturer should be prepared to include the relevant measures and metrics as part of their regulatory submission.

Regardless of the device’s history, Espinosa and Slattery emphasize the importance of having a well-defined plan in place for collecting and reporting on cybersecurity measures and metrics, even if the data is not immediately available. This proactive approach can help medical device manufacturers navigate the regulatory landscape more effectively and demonstrate their commitment to ongoing security improvements.

Conclusion: Embracing Cybersecurity Measures and Metrics for Improved Patient Safety

The FDA’s focus on cybersecurity measures and metrics for medical devices is a clear indication of the growing importance of this issue in the healthcare industry. By understanding the distinction between measures and metrics, and aligning their practices with the agency’s expectations, medical device manufacturers can not only navigate the regulatory landscape more effectively, but also enhance the overall security and safety of their products.

As Espinosa and Slattery have highlighted, the collection and analysis of these data points should be viewed as a starting point for a more comprehensive cybersecurity strategy, one that incorporates risk profiles, actionable insights, and a commitment to continuous improvement. By adopting this approach, medical device manufacturers can play a vital role in ensuring patient safety and maintaining the trust of healthcare providers and the public.

How Blue Goat approaches this

Blue Goat Cyber assists medical device manufacturers in developing and implementing practical cybersecurity measures and metrics that align with FDA expectations. Our methodology involves identifying critical data points, establishing efficient collection processes, and integrating risk-based analysis to prioritize security efforts. We help define relevant measures and translate them into actionable metrics, ensuring that data provides meaningful insights into your device's security posture. Our team, comprised of certified professionals such as CISSPs and former military red team members with OSCP certifications, applies real-world expertise to your unique challenges. We simplify complex requirements, transforming them into manageable tasks for your engineering and quality teams. We offer assistance with /services/fda-premarket-cybersecurity-services, ensuring your submissions meet regulatory standards. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.

FAQ

What is the difference between a cybersecurity measure and a metric?

A measure is a quantifiable attribute, like the time to apply a patch. A metric is a calculation derived from one or more measures, such as the percentage of vulnerabilities patched.

What cybersecurity metrics does the FDA require for medical devices?

The FDA requires tracking the percentage of identified vulnerabilities that are updated or patched, the duration from vulnerability identification to patch availability, and the duration from patch availability to patch deployment.

Does the FDA require cybersecurity metrics for new medical device submissions?

For new devices, the FDA typically requires a plan outlining how measures and metrics will be collected and reported in the post-market phase, rather than a full set of data at initial submission.

How does risk profiling relate to medical device cybersecurity metrics?

Incorporating risk profiles helps manufacturers prioritize vulnerability remediation based on the potential impact on patient safety and the device's operational environment, making metrics more actionable.

Why are post-market cybersecurity measures important?

Post-market measures and metrics demonstrate a manufacturer's ongoing commitment to medical device security, enabling continuous improvement and compliance with FDA surveillance expectations.

Can medical device manufacturers use custom cybersecurity metrics?

While the FDA specifies key metrics, manufacturers can and should incorporate additional measures and metrics that provide actionable insights into their specific device security posture and risk management.